RxDoctor Payments Data

Daina Zhang, MD

Internal Medicine · Saint Louis, MONPI 1952741761

Payments from drug & device makers

$6,971in general payments, 2019–2025

Across 417 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$885
  • Lilly USA, LLC$724
  • Pfizer$656
  • AbbVie$607
  • Amgen$557
  • GSK$556
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$6,953100%
  • Entertainment$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,971 in reported general payments places this provider in the 90th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$58,501
Medicare patients
168
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide75$121,152
EliquisApixaban71$81,838
FarxigaDapagliflozin Propanediol45$58,164
Soliqua 100-33Insulin Glargine/Lixisenatide35$38,201
JardianceEmpagliflozin29$35,892
JanuviaSitagliptin Phosphate18$28,236
MyrbetriqMirabegron24$23,730
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$18,810
MounjaroTirzepatide16$17,776
XareltoRivaroxaban11$14,069
Dabigatran EtexilateDabigatran Etexilate Mesylate30$12,200
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$11,628
ArexvyRsvpref3 Antigen/As01e/Pf41$11,275
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$10,389
Atorvastatin Calcium737$8,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$302$121,15275 claims
PfizerEliquis, Paxlovid$656$86,01096 claims
AstraZenecaFarxiga, Symbicort$885$60,67956 claims
Boehringer IngelheimJardiance, Stiolto Respimat$162$43,35945 claims
GSKTrelegy Ellipta, Arexvy, Anoro Ellipta$556$40,47483 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$273$38,20135 claims
MerckJanuvia$149$28,23618 claims
Astellas Pharma US IncMyrbetriq$67$23,73024 claims
Lilly USA, LLCMounjaro$724$17,77616 claims
Johnson & JohnsonXarelto$196$14,06911 claims
AbbVieSynthroid$607$1,75516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →